AI Article Synopsis
- A new surgical technique was introduced to control fluid flow in patients experiencing late postoperative hypotony after receiving a Baerveldt glaucoma drainage device.
- The method involved inserting a PreserFlo MicroShunt into the Baerveldt tube to modulate outflow resistance, successfully resolving hypotony in two case studies.
- The procedure resulted in immediate and sustained increases in intraocular pressure without the need for additional medication, providing a reliable alternative to traditional tube ligation.
Article Abstract
We report a new surgical technique for controlling flow with a PreserFlo MicroShunt, in patients with late postoperative hypotony, following a Baerveldt glaucoma drainage device implantation. We present 2 cases with late postoperative hypotony after Baerveldt-shunt implantations. In both cases, the outflow resistance of the Baerveldt tube was modulated by the insertion of a PreserFlo MicroShunt into the lumen of the Baerveldt tube. In the first case, the Microshunt was inserted through the distal opening of the tube in the anterior chamber. In the second case, an end plate, sided approach was chosen after opening the conjunctiva. In both cases, the hypotony was successfully treated. The intraocular pressure rose immediately after the procedure, and it remained well controlled within the targeted range during the first postoperative months without additional pressure-lowering medication. This novel surgical technique provided predictable flow reductions, according to the Hagen-Poiseuille equation. This approach offers a valuable alternative to permanent tube ligation.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/IJG.0000000000002061 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Successful resolution of early fibrin occlusion of PreserFlo MicroShunt with Nd:YAG laser treatment: a case report.
Can J Ophthalmol
January 2025
Dalhousie University, Halifax, Nova Scotia, Canada.
Short-Term Safety and Efficacy of PreserFlo™ Microshunt in Patients with Refractory Intraocular Pressure Elevation After Dexamethasone Implant Intravitreal Injection.
J Clin Med
January 2025
Department of Ophthalmology, University of Bonn, 53127 Bonn, Germany.
: The PreserFlo™ MicroShunt (PFMS) is a bleb-forming device considered to be less invasive than traditional glaucoma surgery such as trabeculectomy. This study evaluates the 1-year success rates as well as safety profile of PFMS in patients having high intraocular pressure (IOP) and/or glaucoma refractory to drop therapy with a history of prior intravitreal dexamethasone therapy. : A total of 16 eyes after PFMS implantation due to elevated IOP after intravitreal dexamethasone implant (DEX-I) administration were included in this retrospective cohort study.
View Article and Find Full Text PDFComparison of outcomes with and without intrastent placement during PMS surgery.
Sci Rep
January 2025
Department of Ophthalmology and Visual Science, Kochi Medical School, Kochi University, Kohasu, Oko-cho, Nankoku City, 783-8505, Kochi, Japan.
To assess the efficacy of using a nylon suture as a stent in the PreserFlo MicroShunt (PMS) lumen to prevent postoperative hypotony, 59 eyes that underwent PMS implantation with follow-up for > 6 months were analyzed. Patients were divided into no intrastenting (NST) and intrastenting (ST) groups, with the ST group subdivided into 9 - 0 nylon suture fully placed (9 F), 9 - 0 nylon suture placement in only half of the lumen (9 H), 10 - 0 nylon suture fully placed (10 F), and 10 - 0 nylon suture placement in only half of the lumen (10 H). The distribution was as follows: 23 eyes in the NST group, 10 in the 9 F group, 9 in the 9 H group, 11 in the 10 F group, and 6 in the 10 H group.
View Article and Find Full Text PDFShort-term efficacy and safety of PreserFlo MicroShunt in Japanese patients with medically treated primary open-angle glaucoma.
Jpn J Ophthalmol
January 2025
Department of Ophthalmology, Graduate of Medicine, Faculty of Medicine, The University of Tokyo, Tokyo, Japan.
Purpose: To assess the efficacy and safety of PreserFlo MicroShunt (PMS) combined with mitomycin C in patients with medically treated primary open-angle glaucoma (POAG).
Study Design: A retrospective observational study.
Methods: The study examined 83 eyes from 83 patients with medically treated glaucoma surgery naive POAG.
Structural reversal of disc cupping measured in Bruch's membrane opening-based OCT morphometry after PRESERFLO microshunt implantation for open-angle glaucoma.
BMC Ophthalmol
January 2025
Department of Ophthalmology, Medical Faculty, University Hospital of Cologne, Kerpener Strasse 62, 50937, Cologne, Germany.
Background/ Aims: To analyze the longitudinal change in Bruch's membrane opening minimal rim width (BMO-MRW) and peripapillary retinal nerve fiber layer (pRNFL) thickness using optical coherence tomography (OCT) after implantation of a PRESERFLO® microshunt for surgical glaucoma management in adult glaucoma patients.
Methods: Retrospective data analysis of 59 eyes of 59 participants undergoing implantation of a PRESERFLO microshunt between 2019 and 2022 at a tertiary center for glaucoma management. Surgical management included primary temporary occlusion of the glaucoma shunt to prevent early hypotony.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!